Abstract: The present invention relates to a novel method for preparing substituted biphenylamines

Abstract: The present application relates to novel substituted piperidinylpyrazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired hemostatic disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of heavy menstrual bleeding, postpartum hemorrhage, hemorrhagic shock, hemorrhagic cystitis, gastrointestinal hemorrhage, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

Abstract: The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

Abstract: Pharmaceutically acceptable single parasiticidal agent compositions of imidacloprid for oral delivery to mammals to systemically control targeted blood-sucking or blood-consuming parasites, such as fleas, ticks and certain species of helminthes and scabies.

Abstract: The present invention relates to novel triazole derivatives, to processes for preparing these compounds, to compositions comprising these compounds, and to the use thereof as biologically active compounds, especially for control of harmful microorganisms in crop protection and in the protection of materials and as plant growth regulators.

Abstract: Presented herein are compositions comprising an antioxidant (i), a radiation manager (ii), and one or more of, a plant strengthener (iii), or a plant growth regulator (iv). Also presented herein are compositions comprising a plant strengthener (iii), and one or more of, an antioxidant (i), or a radiation manager comprising a polyoxyalkylene UV absorber (ii). Furthermore, methods of using the disclosed compositions are also provided.

Abstract: The present application relates to novel bicyclic compounds, to compositions comprising these compounds, to their use for controlling animal pests and to processes and intermediates for their preparation.

Abstract: The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, solid tumors, recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells.

Abstract: The present application relates to novel bicyclic compounds, to their use for controlling animal pests and to processes and intermediates for their preparation.

Abstract: The present application relates to novel bicyclic compounds, to compositions comprising these compounds, to their use for controlling animal pests and to processes and intermediates for their preparation.

Abstract: The present invention relates to a novel method of preparing copanlisib, and copanlisib dihydrochloride, to novel intermediate compounds, and to the use of said novel intermediate compounds for the preparation of said copanlisib.

Abstract: The invention relates to a combination of two or more pharmaceutically active substances, of which at least one is a metabolic product (“metabolite”) of the other (“parent substance”), wherein in particular the dosages thereof are selected such that genotypically or phenotypically related variability in the conversion of the parent substance to the metabolite in particular individuals is compensated for.

Abstract: An intracavity probe for use with a magnetic resonance system includes: a pair of coil loops arranged in a phased array configuration; a pair of decoupling circuits; a pair of output cables; and a spacer material positioned adjacent to an anterior surface of the coil loops. Each coil loop has a drive capacitor and a tuning capacitor. Each decoupling circuit is connected across the tuning capacitor of one of the coil loops. Each output cable is connected at a first end thereof across the drive capacitor of one of the coil loops such that each of the drive capacitors is provided with a separate ground. The spacer material assures a predetermined distance between the pair of coil loops and the region of interest, which thereby reduces intensity of the magnetic resonance signals in proximity to the coil loops, maintains SNR at depth within the region of interest and reduces artifacts.

Abstract: A system for delivering to a patient a slurry which includes a fluid and a material that is non-dissolvable or immiscible in the fluid. The system includes a container adapted to contain the slurry and a supernate of the slurry, a syringe adapted to contain the slurry after dilation with the supermate, a fluid path between the syringe and the contents of the container, the fluid path including a needle at least partially disposed within the contents of the container, a plunger disposed in the syringe and adapted to create pressure in the syringe to cause a dilated slurry to flow into the syringe through the fluid path, and a fluidizing systen associated with the container and comprising a holder adapted to move the needle within the container to affect dilation of the slurry with a portion of the supernate.

Abstract: N-(1-Methyltetrazol-5-yl)benzamides of the general formula (I) are described as herbicides. In this formula (I), X, Z and R are radicals such as alkyl and cycloalkyl.

Abstract: The present application relates to novel heterocyclic compounds, to the use thereof for controlling animal pests including arthropods, insects and nematodes, and to processes and intermediates for preparation of the heterocyclic compounds.

Abstract: A connector assembly for a fluid delivery system includes a conical body defining an interior cavity and a discharge outlet, the discharge outlet defining an internal passage in fluid communication with the interior cavity; and a connector removably attached to the discharge outlet. The connector includes a central body configured to be at least partially positioned within the internal passage of the discharge outlet, and an annular connector portion connected to the central body and configured to releasably engage an exterior of the discharge outlet, the central body defining an internal channel within the central body that is in fluid communication with the interior cavity of the conical body when the connector is attached to the discharge outlet.

Abstract: The present invention relates to a composition comprising at least one biological control agent selected from the group consisting of Bacillus chitinosporus AQ746 (NRRL Accession No. B-21618), Bacillus mycoides AQ726 (NRRL Accession No. B-21664), Bacillus pumilus (NRRL Accession No. B-30087), Bacillus pumilus AQ717 (NRRL Accession No. B-21662), Bacillus sp. AQ175 (ATCC Accession No. 55608), Bacillus sp. AQ177 (ATCC Accession No. 55609), Bacillus sp. AQ178 (ATCC Accession No. 53522), Bacillus subtilis AQ743 (NRRL Accession No. B-21665), Bacillus subtilis AQ713 (NRRL Accession No. B-21661), Bacillus subtilis AQ153 (ATCC Accession No. 55614), Bacillus thuringiensis BD#32 (NRRL Accession No. B-21530), Bacillus thuringiensis AQ52 (NRRL Accession No. B-21619), Muscodor albus 620 (NRRL Accession No. 30547), Muscodor roseus A3-5 (NRRL Accession No. 30548), Rhodococcus globerulus AQ719 (NRRL Accession No. B-21663), Streptomyces galbus (NRRL Accession No. 30232), Streptomyces sp. (NRRL Accession No.

Abstract: Disclosed are compounds of formula (I) which possess anthelminthic properties wherein the structural elements have the meaning as indicated in the description. Further disclosed are such compounds for the control, treatment and/or prevention of infections with helminths in animals and humans.

Abstract: The present invention relates to benzim-idazol-2-amines of general formula (I) in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.